ICER's assessment of Biogen's controversial Alzheimer's drug, Aduhelm, was among the most read MHE articles about healthcare costs in 2021.
The U.S. Circuit Court of Appeals of the District of Columbia ruled that the rule could take effect.
The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.
The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.
A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveat the anticipated price, according to the cost-effectiveness group's calculations.